Immunovant, Inc. IMVT
Immunovant, Inc. (Nasdaq: IMVT) is an immunology/inflammation drug developer. Its lead program, IMVT-1402 (imeroprubart), is in Phase 3 for Graves' disease; D2T rheumatoid arthritis; myasthenia gravis; CIDP; Sjogren's disease. Its next catalyst on record is IMVT-1402 D2T RA: Further program updates (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: IMVT-1402 D2T RA — Further program updates (H2 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| IMVT-1402 - Graves' disease (two potentially registrational trials) | Graves' disease | antibody | Phase 3 |
| IMVT-1402 - difficult-to-treat rheumatoid arthritis (potentially registrational) | D2T RA | antibody | Phase 3 |
| IMVT-1402 - myasthenia gravis (potentially registrational) | MG | antibody | Phase 3 |
| IMVT-1402 - CIDP (potentially registrational) | CIDP | antibody | Phase 3 |
| IMVT-1402 - Sjogren's disease (potentially registrational) | SjD | antibody | Phase 3 |
| IMVT-1402 - cutaneous lupus erythematosus (proof of concept) | CLE | antibody | Phase 2 |
Recent results and decisions
- May 20, 2026missed Both batoclimab Phase 3 TED studies did not meet the primary endpoint (topline announced April 2026).
In April 2026, we announced topline results from the two Phase 3 clinical studies evaluating batoclimab for adults with active, moderate-to-severe thyroid eye disease (TED), neither of which met the primary endpoint.
Filing - May 20, 2026discontinued Immunovant discontinued batoclimab development across all indications to focus on IMVT-1402.
Following these results, we discontinued further development of batoclimab across all indications to focus fully on IMVT-1402.
Filing - May 20, 2026positive Open-label Week 16 results in D2T RA (N=170): ACR20/50/70 response rates of 72.7%/54.5%/35.8%; no new safety signals; further updates H2 2026.
At Week 16, the observed ACR20, ACR50, and ACR70 response rates were 72.7%, 54.5%, and 35.8%, respectively; participants who discontinued prior to Week 16 were imputed as non-responders.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.